Ultragenyx Reports Incentive Grant Pursuant to Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on developing and commercializing novel therapies for rare and ultra-rare diseases, today announced the grant of 62,555 restricted stock units of the Company's common stock to 16 newly hired non-executive officers of the Company. The awards were approved by the Compensation Committee of the Company's Board of Directors and were made under the Ultragenyx Employment Inducement Plan with a grant date of September 16, 2024 as incentive material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The Restricted Stock Units vest over a period of four years, with 25% of the underlying shares vesting on each anniversary of the grant date, provided that the employee is continuously employed by the Company on such vesting dates.